Remedy Pharmaceuticals
  • Home
  • Team
  • News
  • Contact

News + Investor Information

Remedy Pharmaceuticals Series B Financing Oversubscribed

7/10/2012

0 Comments

 
PRESS RELEASE
​
Remedy Pharmaceuticals Series B Financing Oversubscribed

Industry Insiders and Sophisticated Financial Investors Show Strong Support for Central Acute Nervous System Drug

New York, NY, USA - July 10, 2012 – Remedy Pharmaceuticals, Inc. today announced it had closed a Series B financing at $3.7 million.

Individuals who participated in the financing included M.D.’s, Ph.D.’s, ex-pharma and biotech executives, and sophisticated financial investors. Capital will be used to further commercialization efforts for Remedy’s lead product, RP-1127, a drug for treating acute central nervous system disorders such as stroke and traumatic brain injury.

“We are delighted to welcome to our new investors. We greatly appreciate their faith in the company and will work diligently and tirelessly to reward the trust they have placed in us,” notes Sven Jacobson, Chief Executive Officer of Remedy. “Millions of people suffer from stroke, traumatic brain injury, spinal cord injury and other acute CNS disorders each year, and we believe we have an opportunity to materially improve their outcomes. This investment will greatly assist in helping us prove the value of RP-1127.”
“What’s particularly encouraging is that many of these investors are experts in this field.” adds David Geliebter, Chairman of Remedy and Managing Partner of Carrot Capital. “Their investments validate the work we have done to date and the potential we all see in RP-1127.”

About RP-1127

Remedy’s lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NCCa-ATP swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a development stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.
​
For more information, email: info@remedypharmaceuticals.com
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    RSS Feed

    Archives

    May 2017
    January 2017
    November 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    October 2015
    September 2015
    August 2015
    July 2015
    May 2015
    February 2014
    July 2013
    February 2013
    October 2012
    July 2012
    February 2012

Copyright © 2021. Remedy Pharmaceuticals, Inc. / Embark Healthcare - All rights reserved.
Website by CG Media LLC
  • Home
  • Team
  • News
  • Contact